PRAISE: providing a roadmap for automated infection surveillance in Europe.

Automated Bloodstream infection Data Electronic health record Healthcare-associated infection Quality Surgical site infection Surveillance

Journal

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
ISSN: 1469-0691
Titre abrégé: Clin Microbiol Infect
Pays: England
ID NLM: 9516420

Informations de publication

Date de publication:
Jul 2021
Historique:
received: 17 11 2020
revised: 24 02 2021
accepted: 27 02 2021
entrez: 4 7 2021
pubmed: 5 7 2021
medline: 3 11 2021
Statut: ppublish

Résumé

Healthcare-associated infections (HAI) are among the most common adverse events of medical care. Surveillance of HAI is a key component of successful infection prevention programmes. Conventional surveillance - manual chart review - is resource intensive and limited by concerns regarding interrater reliability. This has led to the development and use of automated surveillance (AS). Many AS systems are the product of in-house development efforts and heterogeneous in their design and methods. With this roadmap, the PRAISE network aims to provide guidance on how to move AS from the research setting to large-scale implementation, and how to ensure the delivery of surveillance data that are uniform and useful for improvement of quality of care. The PRAISE network brings together 30 experts from ten European countries. This roadmap is based on the outcome of two workshops, teleconference meetings and review by an independent panel of international experts. This roadmap focuses on the surveillance of HAI within networks of healthcare facilities for the purpose of comparison, prevention and quality improvement initiatives. The roadmap does the following: discusses the selection of surveillance targets, different organizational and methodologic approaches and their advantages, disadvantages and risks; defines key performance requirements of AS systems and suggestions for their design; provides guidance on successful implementation and maintenance; and discusses areas of future research and training requirements for the infection prevention and related disciplines. The roadmap is supported by accompanying documents regarding the governance and information technology aspects of implementing AS. Large-scale implementation of AS requires guidance and coordination within and across surveillance networks. Transitions to large-scale AS entail redevelopment of surveillance methods and their interpretation, intensive dialogue with stakeholders and the investment of considerable resources. This roadmap can be used to guide future steps towards implementation, including designing solutions for AS and practical guidance checklists.

Identifiants

pubmed: 34217466
pii: S1198-743X(21)00112-9
doi: 10.1016/j.cmi.2021.02.028
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

S3-S19

Informations de copyright

Copyright © 2021. Published by Elsevier Ltd.

Auteurs

Maaike S M van Mourik (MSM)

Department of Medical Microbiology and Infection Control, University Medical Center Utrecht, the Netherlands. Electronic address: M.S.M.vanMourik-2@umcutrecht.nl.

Stephanie M van Rooden (SM)

Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands; Centre for Infectious Disease Epidemiology and Surveillance National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.

Mohamed Abbas (M)

Infection Control Programme, Geneva University Hospitals, Geneva, Switzerland.

Olov Aspevall (O)

Unit for Surveillance and Coordination, Public Health Agency of Sweden, Solna, Sweden.

Pascal Astagneau (P)

Centre for Prevention of Healthcare-Associated Infections, Assistance Publique - Hôpitaux de Paris & Faculty of Medicine, Sorbonne University, Paris, France.

Marc J M Bonten (MJM)

Department of Medical Microbiology and Infection Control, University Medical Center Utrecht, the Netherlands; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands.

Elena Carrara (E)

Infectious Diseases Section, Department of Diagnostics and Public Health, University of Verona, Italy.

Aina Gomila-Grange (A)

Infectious Diseases Unit, Bellvitge Biomedical Research Institute (IDIBELL), Bellvitge University Hospital, Barcelona, Infectious Diseases Unit, Consorci Corporació Sanitària Parc Taulí, Barcelona, Spain.

Sabine C de Greeff (SC)

Centre for Infectious Disease Epidemiology and Surveillance National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.

Sophie Gubbels (S)

Data Integration and Analysis Secretariat, Statens Serum Institut, Copenhagen, Denmark.

Wendy Harrison (W)

Healthcare Associated Infections, Antimicrobial Resistance and Prescribing Programme (HARP), Public Health Wales, UK.

Hilary Humphreys (H)

Department of Clinical Microbiology, The Royal College of Surgeons in Ireland, Department of Microbiology, Beaumont Hospital, Dublin, Ireland.

Anders Johansson (A)

Clinic for Infectious Diseases, Umea University, Sweden.

Mayke B G Koek (MBG)

Centre for Infectious Disease Epidemiology and Surveillance National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.

Brian Kristensen (B)

Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, Copenhagen, Denmark.

Alain Lepape (A)

Clinical Research Unit, Department of Intensive Care, Centre Hospitalier Universitaire Lyon Sud 69495, Pierre-Bénite, France.

Jean-Christophe Lucet (JC)

Infection Control Unit, Hôpital Bichat-Claude Bernard Assistance Publique - Hôpitaux de Paris, Paris, France.

Siddharth Mookerjee (S)

Infection Prevention and Control Department, Imperial College Healthcare NHS Trust, UK.

Pontus Naucler (P)

Department of Medicine Solna, Division of Infectious Diseases, Karolinska Institutet and Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.

Zaira R Palacios-Baena (ZR)

Unit of Infectious Diseases, Clinical Microbiology and Preventive Medicine, Hospital Universitario Virgen Macarena, Institute of Biomedicine of Seville (I. BIS), Sevilla, Spain.

Elisabeth Presterl (E)

Department of Infection Control and Hospital Epidemiology, Medical University of Vienna, Austria.

Miquel Pujol (M)

Infectious Diseases Unit, Bellvitge Biomedical Research Institute (IDIBELL), Bellvitge University Hospital, Barcelona, Infectious Diseases Unit, Consorci Corporació Sanitària Parc Taulí, Barcelona, Spain.

Jacqui Reilly (J)

Safeguarding Health Through Infection Prevention Research Group, Institute for Applied Health Research, Glasgow Caledonian University, Scotland, UK.

Christopher Roberts (C)

Healthcare Associated Infections, Antimicrobial Resistance and Prescribing Programme (HARP), Public Health Wales, UK.

Evelina Tacconelli (E)

Infectious Diseases, Research Clinical Unit, DZIF Center, University Hospital Tübingen, Germany; Infectious Diseases Section, Department of Diagnostics and Public Health, University of Verona, Italy.

Daniel Teixeira (D)

Infection Control Programme, Geneva University Hospitals, Geneva, Switzerland.

Thomas Tängdén (T)

Department of Medical Sciences, Uppsala University, Uppsala, Sweden.

John Karlsson Valik (JK)

Department of Medicine Solna, Division of Infectious Diseases, Karolinska Institutet and Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.

Michael Behnke (M)

National Reference Center for Surveillance of nosocomial Infections, Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Hygiene and Environmental Medicine, Berlin, Germany.

Petra Gastmeier (P)

National Reference Center for Surveillance of nosocomial Infections, Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Hygiene and Environmental Medicine, Berlin, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH